<DOC>
	<DOCNO>NCT01931982</DOCNO>
	<brief_summary>The purpose study determine GLP-1 agonist improves microvascular perfusion heart patient type 2 diabetes</brief_summary>
	<brief_title>Effect Glucagon-like Peptide 1 ( GLP-1 ) Microvascular Myocardial Function Patients With Type 2 Diabetes .</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes monotherapy metformin sulfonylurea combination therapy metformin sulfonylurea . Age : 2575 year BMI &gt; 25 kg/m2 HbA1c 6,010 % Current treatment insulin Dipeptidyl peptidase IV inhibitor . Haemoglobin &lt; 6.5 mmol/l Documented significant stenosis leave anterior descend artery ( LAD ) coronary angiography CTangiography regional dysfunction document dipyridamol stressechocardiography . If stress test baseline show significant stenosis patient exclude study . Allergy towards victoza Â® ( liraglutide ) , Dipyridamol , Nitroglycerin rescue medicine : Theophyllin Pregnancy Severe asthma Active cancer Severe comorbidity limit lifeexpectancy Estimated glomerular filtration rate ( eGFR ) &lt; 60 ( measure baseline ) Severe hepatic comorbidity Chronic alcohol abuse Heart failure leave ventricular ejection fraction &lt; /= 45 % Atrial fibrillation Chronic previous acute pancreatitis Inflammatory bowel disease .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>diabetes , GLP-1 , Victoza , CFR , microvascular dysfunction</keyword>
</DOC>